Chengdu Puji Traditional Chinese Medicine Research Institute

Lung Tumors and Lung Cancer

Complete English source translation

Lung Tumors and Lung Cancer

Chengdu Puji Traditional Chinese Medicine Research Institute Chengdu Puji TRADITIONAL CHINESE MEDICINE RESEARCH INSTITUTE Traditional Chinese Medicine Outpatient Department Pui Traditional Chinese Medicine case sharing on tumor rehabilitation patient-…

Diagnosis
Lung Tumors and Lung Cancer
Source materials
1 image
English record
794 words

Complete English Translation · Source 1

Chengdu Puji Traditional Chinese Medicine Research Institute

Chengdu Puji TRADITIONAL CHINESE MEDICINE RESEARCH INSTITUTE Traditional Chinese Medicine Outpatient Department

Pui Traditional Chinese Medicine

case sharing on tumor rehabilitation

patient-centered, differentiating treatment based on diagnosis, helping patients live with tumors

patient condition:

Heilongjiang, 65-year-old patient with lung cancer [PATIENT]

examination report shows lung cancer with brain metastasis, surgical resection performed

post-tumor mass, selected traditional Chinese medicine for continuous treatment, initially diagnosed at our hospital in December 2024, reported headache during medication period

Pain and dizziness symptoms have improved; upon follow-up examination in March 2025, significant reduction in intracranial lesions was observed, with lesion extent

significantly reduced.

Verification date N0: 200.12-1

examination region:

9 supply base report (enterprise (m collaboration, examination with medication: 18F-500

tumor

10 doses/1.5 minutes

CT scanning mode and layer thickness: spiral

suitable drug dosage

initial examination report

findings on examination:

mild uptake SUV max: 3.2; left lobe shows unclear appearance, bilateral cerebral hemispheres symmetric, solid tissue radiopharmaceutical distribution

original right side tumor mass resection, partial discontinuity of right superior and lateral bone, slight soft tissue swelling in the area, radiopharmaceutical uptake

fasting state, intravenous injection of 18F-FDG 9.8mCl month

point-like low-density shadows seen in the region, blurred borders, bilateral cerebral sulci and cerebral cisterns widened, all ventricles and cisterns normal in size and shape, midline

generally uniform, left-right symmetric,

seen abnormal radiopharmaceutical uptake increase or low-attenuation foci, poorly uniform solid density, bilateral basal

increased radiopharmaceutical uptake in the region, SUV max: 12.5: oral

evenly distributed, multiple lymph node shadows seen in bilateral neck and cervical regions.

abdominal area shows mild physiological uptake increase, pharynx, larynx

right breast approximately soft tissue mass,

Normal tissue shows mild increased radioactivity uptake,

A brain lesion detected

2.2, pulmonary field shows focal enhancement, bilateral pulmonary texture increased and enhanced, disordered in distribution, a non-regular lesion seen in the lower lobe of left lung near the oblique fissure

Focal nodular tissue density shadow, size approximately: 8*6mm, increased radioactivity uptake SUV max:

Adjacent interlobar pleura shows pleural retraction sign, lesion shows abnormal increased radioactivity uptake SUV max: 7.4: scattered micro-nodules seen in both lungs

Linear tissue-like density shadow, size approximately: 26*9mm, with nodular density increase seen, maximum slice size approximately: 12*8mm,

Abnormal uptake increased SUV max: 8.1: Point-like calcification shadows seen in major vessels and coronary artery course areas, mediastinal pool

High SUV max: 3.2: Bilateral hilar, mediastinal, and right hilar lymph node shadows seen, largest approximately: 425mm radioactivity

Focal, linear, patchy, and reticular density increased shadows, predominantly in the lower lobes of both lungs beneath the pleura, some lesions show increased radioactivity uptake

SUV maximum value in the region of interest (thoracic aortic lcm): 1.8.

Region) SUV max value: 2.8, multiple small cystic low-density shadows seen in the liver, largest with diameter approximately 4mm, no abnormal increased radioactivity uptake detected

Pelvis shows visible bilateral renal and ureteral opacification with diffuse filling defects. Hepatic pool (right hepatic lobe 30mm) shows abnormality

Multiple intestinal tube gas distension shadows observed. Both adrenal glands enlarged, more so on the left, size approximately: 27*17mm, abnormal radioactivity uptake

High. Gastric filling is poor, no obvious FDG metabolic abnormality detected in gastric wall. Intestinal tract shows linear areas of increased radioactivity uptake, intra-abdominal

Increased SUV max: 5.9: Cystic low-density shadow seen, which is isodense

Elective, limb glands, right renal morphology and

Report doctor:

The results of this examination are for reference only by clinical physicians, and should be properly preserved.

Li Shaojie

.0450-[ID REDACTED], [ID REDACTED]

Report date:

2024-12-18

This project is a checking and testing result project in Heilongjiang Province.

Enhanced 1.5T (lung tumor and cranial screening enhanced)

Pathologist 6067

Collection time: 2025-03-27 09:02:55

Examination findings

After 4 months of medication

"Right orbital mass resection post-op" follow-up: after intravenous contrast agent injection, enhanced scan

Description: mild non-uniform enhancement of the right orbital lateral wall and temporal bone. Right frontal lobe, left

in the sella region, patchy and ring-like abnormal enhancing foci are seen, the largest measuring approximately 0.7cm; no abnormal enhancing foci in the rest of the brain parenchyma.

no abnormal enhancing foci in the brain parenchyma; slight enlargement of ventricular system, and slight widening of sulci and gyri.

bed diagnosis

decrease in intracranial lesions

1. Consider 'postoperative changes after right orbital mass resection' based on history; right orbital

heterogeneous enhancement of the lateral wall and temporal bone, 2, multiple intracranial abnormal enhancing foci, combined with history

decreased, lesion range reduced, recommend periodic follow-up.

Consider metastatic tumor; compared to the previous scan in December 2024, the number of lesions has significantly decreased, and the lesion size has shrunk; recommend periodic follow-up.

pharmaceutical 6*

reporting physician 9620

report time 2025-03-27 09:02:55

Would you like a specialist to review your case?

Share a brief history and the reports you already have. One private online consultation is USD $30.